Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

著者: Mark Rigby, Linda A. DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen E. Gitelman, Chetanbabu M Patel, Kurt Griffin, Eva Tsalikian, Peter A. Gottlieb, Carla J. Greenbaum, Nicole Sherry, Wayne V. Moore, Roshanak Monzavi, Steven M. Willi, Philip Raskin, Antoinette Moran, William E. Russell, Ashley Pinckney, Lynette Keyes-Elstein, Michael Howell, Sudeepta Aggarwal, Noha Lim, Deborah Phippard, Gerald T. Nepom, James McNamara, Mario R. Ehlers - The Lancet 2013 被引用: 206